BeiGene abandons ociperlimab over poor phase 3 prospects in latest blow to TIGITs
BeiGene is scrapping ociperlimab over a disappointing phase 3 outlook two years after Novartis handed back the anti-TIGIT antibody.
BeiGene is scrapping ociperlimab over a disappointing phase 3 outlook two years after Novartis handed back the anti-TIGIT antibody.
